IL-33 Contributes to the Pathological Changes of Hair Follicles in Psoriasis: A Potential Target for Psoriatic Alopecia
DOI: https://doi.org/10.2147/CCID.S403075
2023-03-12
Abstract:Chan Dai, 1 Huoying Chen, 2 Mengya Jiao, 1 Na Zhang, 1 Xuhuan Tang, 1 Anqi Fan, 3 Shiwang Liu, 1 Zhigang Qian, 1 Chenchen Wang, 1 Yong Xu, 1 Zheng Tan, 1, 4 Fanfan Zeng, 5 Fang Zheng 1, 4 1 Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China; 2 Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guizhou, People's Republic of China; 3 College of Life Science, Yangtze University, Jingzhou, Hubei, People's Republic of China; 4 Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei, People's Republic of China; 5 Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China Correspondence: Fang Zheng, Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, Hubei, People's Republic of China, Email Fanfan Zeng, Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, Hubei, People's Republic of China, Email Purpose: IL-33 is constitutively expressed in skin tissues. Alopecia, a T cells-driven disorder of the hair follicles (HFs), is a common complication in the development of psoriasis. However, the role of IL-33 in psoriatic alopecia remains uncovered. Here, we investigated the roles of IL-33 in inducing pathological changes of hair follicles in psoriasis. Patients and Methods: Clinical samples and imiquimod (IMQ)-induced psoriatic mice samples were used to investigate the pathological changes and T-cell infiltration of HFs. By using immunohistochemistry staining, the distribution and expression alteration of IL-33 in HFs were determined. Next, by using IL-33 and ST2 knockout mice, we investigated the role of IL-33/ST2 axis in the pathological changes of HFs in psoriasis. Meanwhile, recombinant IL-33 protein was subcutaneous injected to confirm its effect. Finally, RNA sequencing was used to clarify the genes and signaling pathways that involved in this process. Differentially expressed genes were further verified by RT-PCR in cultured HFs in vitro. Results: We found that the pathological changes of HFs and T cells infiltration in imiquimod-induced psoriatic mice were similar to that in psoriasis patients. The IL-33 positive keratinocytes in the outer root sheath of HFs were increased in both psoriasis patients and psoriatic model mice compared with the controls. By using gene knockout mice, we found that the pathological changes and T cell infiltration were attenuated in IL-33 −/− and ST2 −/− psoriatic model mice. In addition, subcutaneous injection of recombinant IL-33 exacerbated the pathological changes of HFs and T cell infiltration. RNA sequencing and RT-RCR revealed that IL-33 upregulated the transcription of genes related to keratinocytes proliferation and T lymphocytes chemotaxis. Conclusion: Our study identifies that IL-33 promotes the pathological changes of HFs in psoriasis, which contributes to psoriatic alopecia. Inhibition of IL-33 may be a potential therapeutic approach for psoriatic alopecia. Keywords: IL-33, psoriatic alopecia, hair follicle, keratinocytes Psoriatic alopecia is one of the most common complications in the development of psoriasis, especially in severe cases. More than 80% of psoriasis patients suffered from alopecia throughout the course of the disease. Psoriasis causes different types of alopecia, including patchy or diffuse alopecia in the psoriatic lesion area, telogen alopecia and scar baldness, among which patchy alopecia accounts for about 75% of patients with psoriasis alopecia. 1 Psoriatic alopecia affects not only the scalp but also other parts of the body. It seriously affects patients' daily life and work, and brings heavy burdens to patients' psychological and social life. 2,3 Several anti-psoriatic drugs show an alleviating effect on psoriatic skin, such as glucocorticoids, cyclosporine A, 4 TNF-α inhibitors, an anti-IL-23 antibody, an IL-17 receptor blocker, and IL-17 inhibitors. 5–7 However, for patients with psoriatic alopecia, those drugs are not satisfactory and cause hair growth disorders. 8,9 Therefore, seeking a treatment that can effectively tre -Abstract Truncated-
dermatology